AstraZeneca’s

AstraZeneca’s newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says

Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder. The Institute for Clinical and… Read More »

AstraZeneca’s diabetes drug Farxiga nabs coveted kidney disease nod, way ahead of rival Jardiance

AstraZeneca’s diabetes med Farxiga stormed the heart failure market with a first-in-class approval last year—and in chronic kidney disease, it just left would-be rival Jardiance in the dust. The FDA late Friday approved Farxiga, also known as dapagliflozin, to treat chronic kidney disease even in patients without diabetes. With that CKD approval in hand, Farxiga… Read More »